Alpelisib (BYL719)

Catalog No.S2814

Alpelisib (BYL719) Chemical Structure

Molecular Weight(MW): 441.47

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 592 In stock
USD 370 In stock
USD 570 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

3 Customer Reviews

  • AN3CA (B), JHUEM2 (D), and MFE296 (H) cells were treated with the indicated doses of BGJ398 and BYL719 alone or in combination for 96 hours, and an SRB assay was subsequently performed.

    Mol Cancer Ther, 2017, 16(4):637-648. Alpelisib (BYL719) purchased from Selleck.

    BYL719 induces Apoptosis in MM cells. The effect of increasing concentrations of BYL719 (0-2.5 umol/l) for 48 h on the apoptosis of MM1s cells. The effect of BYL719 on the apoptosis signalling; cleaved PARP, caspase 3, caspase 9 by Western blotting. MM, multple myeloma.

    Br J Haematol 2014 165(1), 89-101. Alpelisib (BYL719) purchased from Selleck.

  • A549 cell was trypsinized and plated at 50% confluence in DMEM. 16 hours later, BYL719 was added at final concentrations of 0, 1, 5, 10 and 20uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- AKT, pS473-AKT, pT286-CyclinD1 and beta-actin (internal control) antibodies.

    Alpelisib (BYL719) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
5 nM
In vitro

BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 NVTWbmx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSwMlEuOTByIN88US=> NYi3dIFSPzJiaB?= Mo\nTWM2OD1zLkGwJO69VQ>? NXjmb5ZkOjV3NUC1OFk>
SNU-1076 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlniNE4yNTFyMDFOwG0> MlTMO|IhcA>? NVTSXGM5UUN3ME22MlgzKM7:TR?= NYTDVXdqOjV3NUC1OFk>
SNU-1066 M136[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2njT|AvOS1zMECg{txO MkT3O|IhcA>? MVLJR|UxRTFwMUOg{txO MkG4NlU2PTB3NEm=
FaDu M2PmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuzNE4yNTFyMDFOwG0> Mn7ZO|IhcA>? NYj2bHFyUUN3ME2xPU43PiEQvF2= MXGyOVU2ODV2OR?=
SNU1041 NUmyT5VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMlEuOTByIN88US=> NHXzSYM4OiCq NH;iNFdKSzVyPUKwMlY2KM7:TR?= MUWyOVU2ODV2OR?=
SCC25 NUTvfmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDzRpoxNjFvMUCwJO69VQ>? M{HDUlczKGh? NIH4WIVKSzVyPUS5MlMxKM7:TR?= NWDyb5Y{OjV3NUC1OFk>
BON-1 NUW0VFd3TnWwY4Tpc44hSXO|YYm= NFvhS4EyNzFyIN88US=> M4DSd|QhcA>? MmTnbY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN? M1jxOFI2ODJ4Mkmy
QGP-1 Mon2SpVv[3Srb36gRZN{[Xl? NVnhe|lEOS9zMDFOwG0> NYnoeG9uPCCq Mn\LbY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN? M2TISlI2ODJ4Mkmy
MG-63 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW1PVFKSzVyPU[g{txO97zOIFnDPVA:OjRizszN MXSyOFk3OTd7MB?=
HOS NEe2T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jYRmlEPTB;MUWg{txO97zOIFnDPVA:PDJizszN NYW2R3Y6OjR7NkG3PVA>
MOS-J M2HWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHyfW9XUUN3ME2xNEDPxE4xvJygTWM6OD1|NjFOwG0> NYnY[ZNLOjR7NkG3PVA>
POS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRThizszN89yNKEmFOUC9N|Yh|ryP NEfOclgzPDl4MUe5NC=>
92.1 M2Kwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX61NFAuOjByMDDuUS=> MlniOUBl NVjZcoZQcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? NHnKUlUzPDV4M{W0NC=>
Mel270 M3rWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XZ[lUxOC1{MECwJI5O MUO1JIQ> MWjpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> NW\0W5d5OjR3NkO1OFA>
Omm1.3 M2HMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP1ZZBSPTByLUKwNFAhdk1? MoXYOUBl MVXpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> MmTMNlQ2PjN3NEC=
Omm1 NHvVdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTlPGhTPTByLUKwNFAhdk1? M4S1bVUh\A>? Mo\ubY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> MV2yOFU3OzV2MB?=
C918 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjGVZc2ODBvMkCwNEBvVQ>? NHjrR|Y2KGR? Ml3ybY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> NFmwPIszPDV4M{W0NC=>
Mel290 NYX0NYJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\nUFUxOC1{MECwJI5O MX21JIQ> NIHURnNqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? NXfsRnU6OjR3NkO1OFA>
OPM2 NIXNbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H3NVAvPS1{LkWg{txO MYe0PEBp MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;5NXYzPDRyNUGyNS=>
OPM1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzCNE42NTJwNTFOwG0> NV72WllnPDhiaB?= M1vVfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV2yOFQxPTF{MR?=
U266 NXTPfVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlUuOi53IN88US=> NGi1e5E1QCCq NF7uSYpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUmyOFQxPTF{MR?=
MM1R NYTONFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMlUuOi53IN88US=> MW[0PEBp NY\XepVQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWWyOFQxPTF{MR?=
MM1S M{fCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMlUuOi53IN88US=> NFfwW3I1QCCq M{fwNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH;mNHgzPDRyNUGyNS=>
H929 M{nHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlUuOi53IN88US=> NWPmOmxFPDhiaB?= NX3SSFFycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmC2NlQ1ODVzMkG=
RPMI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjVlAvPS1{LkWg{txO MUC0PEBp MmDPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF3qZpozPDRyNUGyNS=>
SKBR3 NU\EfWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M124XFM{KM7:TR?= NVvPT2lQPSCm NImy[WpqdmirYnn0d{A{Pe,:hTDj[YxtKGe{b4f0bC=> MYmyN|kyQDd7Nx?=
MDA453 NYHxc|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rvSVM{KM7:TR?= MlHSOUBl M3rFTYlvcGmkaYTzJFM597zHIHPlcIwh\3Kxd4To MoHSNlM6OTh5OUe=
EFM192A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnIN|Mh|ryP M{G1OVUh\A>? MYXpcohq[mm2czCyO-+9jSClZXzsJIdzd3e2aB?= MojhNlM6OTh5OUe=
AU565 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSzN|Mh|ryP NXq2N4l{PSCm MnXHbY5pcWKrdIOgNlbwxIViY3XscEBoem:5dHi= Mon1NlM6OTh5OUe=
MDA361 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjN[HU{OyEQvF2= M2jOWFUh\A>? MXzpcohq[mm2czC0OQ+9jSClZXzsJIdzd3e2aB?= MmPFNlM6OTh5OUe=
BT474 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsWG8{OyEQvF2= NIjoTZc2KGR? NVTBSopFcW6qaXLpeJMhOTcxvJWgZ4VtdCCpcn;3eIg> NXvDe4c1OjN7MUi3PVc>
HCC202 M4fofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyzN{DPxE1? Ml\oOUBl NWr0TnNFcW6qaXLpeJMhOjExvJWgZ4VtdCCpcn;3eIg> M336OFI{QTF6N{m3
KPL4 NFrve29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGzN{DPxE1? Mkn1OUBl NGfnNlZqdmirYnn0d{A2QO,:hTDj[YxtKGe{b4f0bC=> NXPreZdWOjN7MUi3PVc>
NCL-N87 NHHnenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6zN{DPxE1? NYT2b2xPPSCm M1LmWIlvcGmkaYTzJFMy97zHIHPlcIwh\3Kxd4To MWWyN|kyQDd7Nx?=
UACC812 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq0b|Q{OyEQvF2= NEXKTZA2KGR? NVPDT2JDcW6qaXLpeJMhOjgxvJWgZ4VtdCCpcn;3eIg> NWrkb4xjOjN7MUi3PVc>
HCC2218 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnwcZc{OyEQvF2= NHr2eZU2KGR? M2LCXolvcGmkaYTzJFE297zHIHPlcIwh\3Kxd4To MVuyN|kyQDd7Nx?=
HCC1569 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLWN|Mh|ryP M1;tO|Uh\A>? NFjMNJNqdmirYnn0d{A297zHIHPlcIwh\3Kxd4To MoXXNlM6OTh5OUe=
OE19 NH31VYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfYTYtOOzNizszN NETmdmI2KGR? Ml7EbY5pcWKrdIOgNlPwxIViY3XscEBoem:5dHi= NIDEUIQzOzlzOEe5Oy=>
OE33 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwbYpyOzNizszN MYW1JIQ> M4X0PYlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To M{KwelI{QTF6N{m3
JIMT1 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nKdlM{KM7:TR?= MYm1JIQ> NVvLcXFvcW6qaXLpeJMhQe,:hTDj[YxtKGe{b4f0bC=> MX6yN|kyQDd7Nx?=
HCC1954 NVnoXYdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKzN{DPxE1? M3TKdlUh\A>? MmHkbY5pcWKrdIOgNlnwxIViY3XscEBoem:5dHi= M1fMblI{QTF6N{m3
NUGC4 M3\BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TP[lM{KM7:TR?= NYrkfWpWPSCm M1\X[4lvcGmkaYTzJFE197zHIHPlcIwh\3Kxd4To MWmyN|kyQDd7Nx?=
ZR-75-30 M4TKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7kfmtXOzNizszN NXvlSXRTPSCm MlvrbY5pcWKrdIOgMVE297zHIHPlcIwh\3Kxd4To NUDQ[3ZZOjN7MUi3PVc>

... Click to View More Cell Line Experimental Data

In vivo BYL719(>270 mg/d) shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients. [1]

Protocol

Solubility (25°C)

In vitro DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 441.47
Formula

C19H22F3N5O2S

CAS No. 1217486-61-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03207529 Not yet recruiting Malignant Neoplasm of Breast M.D. Anderson Cancer Center|Novartis|Astellas Pharma Global Development Inc. March 31 2019 Phase 1
NCT03207529 Not yet recruiting Malignant Neoplasm of Breast M.D. Anderson Cancer Center|Novartis|Astellas Pharma Global Development Inc. March 31 2019 Phase 1
NCT03631953 Not yet recruiting Meningioma Assistance Publique Hopitaux De Marseille January 1 2019 Phase 1
NCT03631953 Not yet recruiting Meningioma Assistance Publique Hopitaux De Marseille January 1 2019 Phase 1
NCT03601507 Recruiting CDKN2A-p16 Positive|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 University of Arizona|National Cancer Institute (NCI) December 14 2018 Phase 2
NCT03601507 Recruiting CDKN2A-p16 Positive|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 University of Arizona|National Cancer Institute (NCI) December 14 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products4

Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID